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Current topics for dyslipidemia are described. Elderly people receiving statin (n=326,981) for 
6.8 years showed reduced hazard ratio (HR) as total mortality 0.75, and cardiovascular 
mortality 0.80. Taking n-3 unsaturated fatty acids >3g daily reduced relative ratio (RR) as 
sudden death 0.70, stroke 0.74 and cardiac death 0.82. As LDL-C is reduced every 1.0 
mmol/L (38.67 mg/dL), cardiovascular event will be reduced by 21%. The efficacy of 
inclisiran has been reported for reducing LDL-C value. In large RCTs of ORION 10/11 
studies, patients with atherosclerotic cardiovascular disease (ASCVD) receiving inclisiran for 
510 days showed decreased LDL-C ratio as 53.8%/49.2%. 
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Commentary   
In recent years, various medical developments have been found 
in dyslipidemia [1]. What about the clinical effects of statins on 
the elderly and people with low cardiovascular risk? It seems 
not so satisfactory in the light of actual life extension. In the 
elderly, high level of LDL-C is not the only factors affecting the 
risk of developing atherosclerosis. For cardiovascular risk, the 
effects of n-3 unsaturated fatty acids may increase in a dose-
dependent manner. However, in actual practice, the clinical 
effect is not apparent. What is the effect of improving the 
prognosis of dyslipidemia agents other than statins, such as 
inclisiran? [2]. In this articles, current topics concerning 
dyslipidemia will be described. A cohort study was reported that 
examined the effect of statin treatment in the elderly on the 
primary prevention of cardiovascular disease [3]. The study 
included 326,981 US veterans aged >75 (mean 81.1 years, 97% 
male, 91% white). After 6.8 years follow-up, cardiovascular 
mortality per 1000 man-years was 22.6 for statin users and 25.7 
for non-users. Propensity score matching-corrected hazard ratio 
(HR) was 0.75 for total mortality, 0.80 for cardiovascular 
mortality, and 0.92 for arteriosclerotic cardiovascular events, 
which were significantly lower for statin users. In this study, 
special group of veterans was analyzed. Then, these results 
cannot be generalized, and the external validity is not always 
high [3]. Patients receiving statin treatment themselves may 
potentially have higher health levels than those who do not.  
A secondary analysis of Aspirin in Reducing Events in the Elderly 
(ASPREE) study was reported on the efficacy of statins in healthy 
elderly people [4]. ASPREE is an RCT that examined the effect of 
aspirin on healthy life expectancy in 19,114 people aged 65 and 
over. This secondary analysis included 18,096 ASPREE 
participants aged 70 years and older (median 74.2 years, 56.0% 
female). The group who was taking statins at the start of the study 
was compared to the group who was not taking statins. Survival 
situation without disability (combined outcomes of total mortality, 
dementia, and persistent physical dysfunction) was examined. A 
median follow-up of 4.7 years showed no significant difference 
between statin use and unimpaired survival (HR 0.92).  
A systematic review was also reported on the cardiovascular 
prognosis of statins in the frail elderly [5]. Six cohort studies were 
included in the review, and no RCTs that met the acceptance 
criteria were reported. In addition, no studies have been reported 
examining the effects on primary prevention or the results on 
cardiovascular events. Some studies in the secondary prevention 
showed a reduced risk of death (HR 0.28) [5].  
In general, the effect of a drug is often indicated by a relative ratio 
of event incidence. In particular, cardiovascular drugs are rarely 
evaluated from their effects on life extension. Under these 
circumstances, a meta-analysis was reported that examined the 
effect of statins on life extension using previously reported RCT 
data [6]. Nineteen placebo-controlled RCTs in at least 1000 
subjects were included. As a result, the number of days of 
postponement of events (days and [95% CI]) during statin follow-
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up compared to placebo was 9.27 days [3.6-14.91] for 
cardiovascular death, 1.5 days [-2.2-5.3] for non-cardiovascular 
death, 18 days [12.1 to 24.1] for myocardial infarction and 6.1 
days [2.86 to 09.39] for stroke [6]. Thus, a meta-analysis 
revealed the life-prolonging effect of statins. In other words, it 
should be noted that the research results shown as relative ratios 
tend to be estimated with the drug effect as an issue. 
Considering the practical life-prolonging effect, it seems to be 
smaller than the level expected so far.  
Several systematic review meta-analyses have been reported on 
the effects of n-3 unsaturated fatty acids on cardiovascular 
disease. Rizo et al. conducted a review [7], including a double-
blind RCT 17 study (n=83,617) with a follow-up period of 1 
year or longer. As a result, it has been shown that the higher the 
dose of n-3 unsaturated fatty acids, the greater the benefit 
obtained. Less than 1 g daily did not reduce the risk of 
cardiovascular disease. At 2 g daily, a significant reduction in 
cardiac death was shown. The relative risk is RR = 0.55. 
Furthermore, administration of 3 g or more per day reduces the 
risk of sudden death (0.70), stroke (0.74) and cardiac death (RR: 
0.82) [7]. 
A systematic review was reported on the factors affecting the 
medication adherence of cardiac statins [8]. Evaluating nine 
reviews, high social and economic status, high education levels, 
and middle-aged age had a positive impact on medication 
adherence. On the other hand, reduced medication adherence 
was observed in women and young, older, non-white races, low 
socio-economic status, new statin users, high out-of-pocket 
costs, experience of reverse effects, dosage/dose complexity, 
high potent level of statins, smoking and drinking habits, poor 
efficacy, and distrust of medical care [8]. The efficacy of 
inclisiran has been reported in patients with elevated LDL-C 
value. ORION-10 study in patients with atherosclerotic 
cardiovascular disease (ASCVD) was conducted. Successively, 
ORION 11 study in patients with ASCVD or at risk equivalent 
to ASCVD was investigated [9]. Both trials were RCTs 
comparing the inclisiran (284 mg) group and the placebo group, 
which were followed for 540 days. Inclisiran was injected 
subcutaneously on days 1 and 90, and every 6 months thereafter, 
and the ratio of change in in LDL-C was investigated as the 
primary outcome. As a result, the LDL-C level on day 510 
decreased by 53.8% in the ORION-10 study and 49.2% in the 
ORION-11 study. Both were significantly different compared to 
the placebo (p<0.001). On the other hand, inclisiran showed 
more adverse events at the injection site than placebo. Elevated 
LDL-C has brought atherosclerosis from pathophysiological 
development, and then lowering LDL-C would be important to 
reduce the risk of ASCVD. As LDL-C is reduced every 1.0 
mmol/L (38.67 mg/dL), CV event will be reduced by 21% [10]. 
Among these circumstances, physiological regulator of LDL-C 
that is serine-protease PCSK9, would promote the degradation 
of LDL receptor. Cost-effectiveness of inclisiran was analyzed, 
based on the ORION-10 trial for the costs and outcomes [11]. As a 
result, the cost of inclisiran should be 60% lower than that of 
evolocumab. In summary, future research development concerning 
LDL-C will be expected so as to prevent ASCVD [12]. 
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